FIGURE 1.
rMSC administration ameliorated HFD‐induced dyslipidaemia and steatosis in liver. Protocol for rMSC therapy in high‐fat diet–fed rats (A): After 18 wk of HFD feeding, SD rats were separated into two groups, one group received two doses of 2 × 106 rMSCs (HFD + MSCs group, n = 6). The other group received the vehicle (HFD group, n = 6). Both groups were fed HFD during all study period (24 weeks). A third group of rats was fed exclusively with regular diet (control group, n = 6). Changes in bodyweight (B) and food intake (C) in three groups. Macroscopic image of liver (top), H&E staining (middle) and Oil Red O staining (bottom) of liver sections of the three groups at the 24th week (D). Liver/bodyweight ratio (E), levels of liver TG and liver TC (F), serum levels of AST, ALT (G) and lipid (H) in the three groups. And the mRNA levels of lipid metabolism‐relative genes in the liver tissues of the three groups (I), and the experiment was repeated 3 times independently. The data are expressed as mean ± SD, *P < .05 vs the control group; # P < .05 vs the HFD group